Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4
Age, y	72	71	66	64
Sex	Male	Female	Male	Female
Preexisting conditions and past medical history	Radioiodine-treated autoimmune thyroiditis	Latent hyperthyroidism, nodular goiter, breast cancer, stroke	Hypertension, mild thrombocytopenia	Hypertension, chronic obstructive pulmonary disease, steatosis hepatis
Allergies	Pollen	None	None	None
Medication on admission	None	Aspirin, metamizole, denosumab (once every 6 mo)	Amlodipine, valsartan, hydrochlorothiazide, tamsulosin	Candesartan, hydrochlorothiazide, zolpidem, salbutamol, tilidine, tiotropium bromide
Time from vaccination to admission, days	11	11	2	15
Symptoms	Petechiae, epistaxis, headache	Petechiae, hyposphagma	Petechiae	None
Platelet count nadir × 10⁹/L	<5	<5	<5	6
D-dimer peak, mg/L (reference range, 0.21-0.52 mg/L FEU)	0.83	1.16	0.35	0.51
PF4-polyanion antibodies (ELISA)	Negative	Negative	Negative	Negative
Treatment	Intravenous immunoglobulin, glucocorticoids	Intravenous immunoglobulin, glucocorticoids, thrombopoietin receptor agonist	Glucocorticoids	Glucocorticoids

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4
Age, y	72	71	66	64
Sex	Male	Female	Male	Female
Preexisting conditions and past medical history	Radioiodine-treated autoimmune thyroiditis	Latent hyperthyroidism, nodular goiter, breast cancer, stroke	Hypertension, mild thrombocytopenia	Hypertension, chronic obstructive pulmonary disease, steatosis hepatis
Allergies	Pollen	None	None	None
Medication on admission	None	Aspirin, metamizole, denosumab (once every 6 mo)	Amlodipine, valsartan, hydrochlorothiazide, tamsulosin	Candesartan, hydrochlorothiazide, zolpidem, salbutamol, tilidine, tiotropium bromide
Time from vaccination to admission, days	11	11	2	15
Symptoms	Petechiae, epistaxis, headache	Petechiae, hyposphagma	Petechiae	None
Platelet count nadir × 10⁹/L	<5	<5	<5	6
D-dimer peak, mg/L (reference range, 0.21-0.52 mg/L FEU)	0.83	1.16	0.35	0.51
PF4-polyanion antibodies (ELISA)	Negative	Negative	Negative	Negative
Treatment	Intravenous immunoglobulin, glucocorticoids	Intravenous immunoglobulin, glucocorticoids, thrombopoietin receptor agonist	Glucocorticoids	Glucocorticoids

ELISA, enzyme-linked immunosorbent assay; FEU, fibrinogen equivalent units.